BR112022013940A2 - Receptores de antígenos quiméricos para eliminação de amiloides - Google Patents
Receptores de antígenos quiméricos para eliminação de amiloidesInfo
- Publication number
- BR112022013940A2 BR112022013940A2 BR112022013940A BR112022013940A BR112022013940A2 BR 112022013940 A2 BR112022013940 A2 BR 112022013940A2 BR 112022013940 A BR112022013940 A BR 112022013940A BR 112022013940 A BR112022013940 A BR 112022013940A BR 112022013940 A2 BR112022013940 A2 BR 112022013940A2
- Authority
- BR
- Brazil
- Prior art keywords
- ayloid
- elimination
- chimeric antigen
- antigen receptors
- chimeric
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 2
- 230000008030 elimination Effects 0.000 title abstract 2
- 238000003379 elimination reaction Methods 0.000 title abstract 2
- 108700010039 chimeric receptor Proteins 0.000 abstract 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
RECEPTORES DE ANTÍGENOS QUIMÉRICOS PARA ELIMINAÇÃO DE AMILOIDES. A presente invenção refere-se a receptores quiméricos compreendendo regiões de ligação às proteínas amiloides, bem como células compreendendo os receptores quiméricos. Também são fornecidos neste documento métodos de tratamento de doenças baseadas em proteínas amiloides por administração de uma célula compreendendo um receptor quimérico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062962763P | 2020-01-17 | 2020-01-17 | |
PCT/US2021/013727 WO2021146620A2 (en) | 2020-01-17 | 2021-01-15 | Chimeric antigen receptors for removal of amyloid |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022013940A2 true BR112022013940A2 (pt) | 2022-09-20 |
Family
ID=76864318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022013940A BR112022013940A2 (pt) | 2020-01-17 | 2021-01-15 | Receptores de antígenos quiméricos para eliminação de amiloides |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230068507A1 (pt) |
EP (1) | EP4090362A4 (pt) |
JP (1) | JP2023510603A (pt) |
KR (1) | KR20220129026A (pt) |
CN (1) | CN115175693A (pt) |
AU (1) | AU2021208630A1 (pt) |
BR (1) | BR112022013940A2 (pt) |
CA (1) | CA3164691A1 (pt) |
IL (1) | IL294740A (pt) |
MX (1) | MX2022008687A (pt) |
WO (1) | WO2021146620A2 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109553686A (zh) * | 2017-09-26 | 2019-04-02 | 南京安吉生物科技有限公司 | 一种新型可调控的双嵌合抗原受体t细胞及其构建方法和应用 |
WO2022120378A1 (en) * | 2020-12-04 | 2022-06-09 | University Of Tennessee Research Foundation | Method for diagnosing amyloid diseases |
WO2024050478A1 (en) * | 2022-09-02 | 2024-03-07 | University Of Tennessee Research Foundation | Chimeric antigen receptors for removal of amyloid |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2689680C (en) * | 2007-05-14 | 2017-11-07 | Novimmune Sa | Fc receptor-binding polypeptides with modified effector functions |
US10213506B2 (en) * | 2014-08-26 | 2019-02-26 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
US20180186855A1 (en) * | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
US11382974B2 (en) * | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
CN109837246A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向ror1的嵌合抗原受体t细胞及其制备方法和应用 |
EP3746468A4 (en) * | 2018-02-02 | 2021-12-01 | The Trustees of The University of Pennsylvania | MODIFIED MONOCYTE / MACROPHAGE / DENDRITIC CELLS EXPRESSING CHIMERA ANTIGEN RECEPTORS AND USES IN DISEASES AND DISORDERS RELATED TO PROTEIN AGGREGATES |
-
2021
- 2021-01-15 BR BR112022013940A patent/BR112022013940A2/pt unknown
- 2021-01-15 JP JP2022543410A patent/JP2023510603A/ja active Pending
- 2021-01-15 MX MX2022008687A patent/MX2022008687A/es unknown
- 2021-01-15 CN CN202180015824.4A patent/CN115175693A/zh active Pending
- 2021-01-15 KR KR1020227027772A patent/KR20220129026A/ko unknown
- 2021-01-15 CA CA3164691A patent/CA3164691A1/en active Pending
- 2021-01-15 US US17/793,355 patent/US20230068507A1/en active Pending
- 2021-01-15 EP EP21741748.4A patent/EP4090362A4/en active Pending
- 2021-01-15 AU AU2021208630A patent/AU2021208630A1/en active Pending
- 2021-01-15 WO PCT/US2021/013727 patent/WO2021146620A2/en unknown
-
2022
- 2022-07-13 IL IL294740A patent/IL294740A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022008687A (es) | 2022-10-27 |
WO2021146620A2 (en) | 2021-07-22 |
CN115175693A (zh) | 2022-10-11 |
WO2021146620A3 (en) | 2021-09-23 |
US20230068507A1 (en) | 2023-03-02 |
EP4090362A2 (en) | 2022-11-23 |
EP4090362A4 (en) | 2024-02-28 |
AU2021208630A1 (en) | 2022-07-21 |
JP2023510603A (ja) | 2023-03-14 |
KR20220129026A (ko) | 2022-09-22 |
IL294740A (en) | 2022-09-01 |
CA3164691A1 (en) | 2021-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022013940A2 (pt) | Receptores de antígenos quiméricos para eliminação de amiloides | |
PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
EA201792420A1 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
BR112018067679A2 (pt) | células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso | |
CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
CY1119283T1 (el) | Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii | |
BR112015021819A2 (pt) | Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19 | |
CR20190095A (es) | Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
AR093788A1 (es) | Inmunoterapia con agentes de enlace | |
MX2020004741A (es) | Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos. | |
BR112017017867A2 (pt) | métodos e composições para tratamento de doenças oculares genéticas | |
DOP2014000007A (es) | Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada | |
BR112012009854B8 (pt) | proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma | |
AR067666A1 (es) | Proteinas de union al antigeno del receptor de il-18 | |
BR112017027498A2 (pt) | anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença. | |
BR112015010360A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que pode se ligar especificamente ao sítio ii de uma il-6 humana, seus usos, ácido nucleico, composição, vetor, célula, e processo para produzir a mesma | |
BR112014017814A8 (pt) | Anticorpos anti-cxcr3 | |
BR112021019411A2 (pt) | Métodos para a produção de células car-nk e uso das mesmas | |
CL2012002081A1 (es) | Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria. | |
UY30525A1 (es) | Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos | |
BR112018070534A2 (pt) | inibição de tgfbeta em imunoterapia | |
BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
PE20190371A1 (es) | Anticuerpos de interferon beta y usos de los mismos |